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ABBREVIATIONS
APOA4 – apolipoprotein a-IV
AR – (human) androgen receptor
BPH – benign prostatic hyperplasia
CRC – colorectal cancer
FLNA – filamin A
FXI – coagulation factor XI
FXII – coagulation factor XII
HAI-1 – hepatocyte growth factor activator inhibitor type 1
HEG1 – protein HEG homolog 1
HDAC1 – histone deacetylase 1
HRG – histidine rich glycoprotein
LC-MS/MS – liquid chromatography-mass spectrometry
MMP-2 – matrix metalloproteinase 2
MMP-9 – matrix metalloproteinase 9
MSNs – mesoporous silica nanoparticles
NCI – National Cancer Institute
NF-kB – nucclear factor-kappa B
NSpC – normalized spectral counts
PAI-1 – plasminogen activator inhibitor-1
PCA – prostate cancer
PSA – prostate-specific antigen
siRNA – small interfering RNA
TGA – thermogravimetric analysis
uPA – urokinase -type plasminogen activator
uPAR – uPA-receptor
VEGF – vascular endothelial growth factor
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ABSTRACT

Prostate cancer is a significant public health concern among American men. The current
screening method for prostate cancer relies on elevated levels of prostate-specific antigen (PSA),
which can be unreliable. Alternatively, a protein "fingerprint" identifies a characteristic set of
proteins indicative of disease. Previous research in this laboratory group has identified a baseline
protein fingerprint for prostate cancer. Here, an analysis is performed to identify how the protein
fingerprint changes in composition throughout disease progression through inspection of the
proteomic composition of human serum and review of the current scientific literature to
investigate why these proteins might be dysregulated with respect to the metabolic activity of
malignant cells. It was found that different disease states (metastasis, positive biopsy, negative
biopsy, and healthy control) had distinctly different sets of upregulated and downregulated
proteins. These dysregulated proteins had varying levels of relevance to physiological
mechanisms involved in the progression of prostate cancer, with some proteins having a clearly
defined role in cancer development while other proteins had unclear roles and appeared to have
primarily diagnostic value at this time, elucidating areas for potential further research. Together
these results provide a better understanding of the metabolic progression and consequences of
prostate cancer, potentially contributing to earlier, more accurate diagnosis in the future.
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I.

INTRODUCTION & BACKGROUND LITERATURE

Cancer is a well-known and widespread public health issue, with prostate cancer at the
top of the list of concern for American men. The American Cancer Society cancer statistics for
2019 state that prostate, lung and bronchus, and colorectal cancers accounted for 42% of all
cases in men, with prostate cancer alone accounting for nearly 1 in 5 new diagnoses. 1 The
statistics for prostate cancer can be tricky, however, as incident rates have reflected some
unusual trends in the past, with rates spiking dramatically in the late 1980s and early 1990s and
more recent trends from 2011-2015 reflecting accelerated declines of approximately 7% per year
for prostate cancer (which is significant when compared to 3% per year for cancers of the lung
and colorectum).1 These unusual trends have been attributed to the fact that diagnosis relies on
elevated levels of prostate-specific antigen (PSA), a protein produced by the prostate gland, as
the primary criterion. PSA, an androgen-regulated serine protease, is produced by prostate
epithelial cells and functions to cleave semenogelins in the seminal coagulum as part of semen
production.2 However, inflammation, aging, and other problems unrelated to cancer can also
elevate PSA levels, making it an unreliable biomarker. This caused a surge in the detection of
asymptomatic disease as a result of widespread PSA testing among previously unscreened men
in the 1980s followed by a sharp drop in prostate cancer incidence, not as a result of significant
change in disease prevalence, but rather decreased PSA testing from 2008 to 2013 in the wake of
US Preventive Services Task Force recommendations against the routine use of the test because
of growing concerns about overdiagnosis and overtreatment. 3
Multiple studies have determined PSA to be an unreliable biomarker for prostate cancer
as it lacks specificity for the prostate cancer disease state, limiting its use in diagnosis and
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potential for early detection of disease, a critical factor in the treatment of cancers and improving
prognosis.4, 5 The current standard for PSA in the detection of prostate cancer is unreliable given
that ∼20 % of men with PSA levels <4 ng/ml have prostate cancer and that many men with
higher levels do not have prostate cancer where 4 ng/ml is defined as the upper limit of normal. 6
Despite this data, PSA is still the most used biomarker and the prevalence of prostate cancer in
combination with the inaccuracy of diagnosis via PSA has prompted the search for novel,
accurate and more reliable biomarkers for the disease.
The National Cancer Institute (NCI) defines ‘biomarker’ as a biological molecule found
in blood, other body fluids, or tissues that can be objectively measured and evaluated as a sign of
a normal/abnormal biological process and a pathogenic condition or disease. 6 Studies have
identified many potential biomarkers of prostate cancer through various techniques, including via
protein biochip surface enhanced laser desorption/ionization mass spectrometry coupled with an
artificial intelligence learning algorithm to differentiate prostate cancer from noncancer cohorts, 4
iTRAQ 3D liquid chromatography with mass spectrometric detection (LC-MS), 7 metabolomics
analysis using magnetic resonance spectroscopy, mass spectrometry and gas chromatography, 8
and protein adsorption onto mesoporous silica nanoparticles coupled with LC-MS to create a
proteomic profile,9 among other methods. In other words, a wide range of potential biomarkers
for prostate cancer have been discovered with promising potential to replace the unreliable PSA
test, including amino acids, lipids and metabolites involved in energy metabolism, 8 hundreds of
proteins, and some non-FDA approved biomarkers including gene markers, RNA, miRNAs, and
mitochondrial DNA.6 Additional research is needed to determine which biomarkers are the most
significant, effective, and accurate in diagnosis. Here, a “protein fingerprint” of the proteomic
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composition in prostate cancer is proposed as a minimally invasive, inexpensive, and clinically
accurate way to identify prostate cancer.
This work is relevant to public health because prostate cancer is highly prevalent, can
detrimentally affect quality of life, and can be fatal, yet despite these significant negative aspects
it is commonly misdiagnosed or diagnosed later than necessary due to the inaccuracy of the
current screening methods. Diagnosis commonly results in false positive or negative results,
causing both psychological stress and biological impacts to patient health in the case that no
disease is present or by delaying diagnosis to a point that could worsen prognosis, prompting the
need for a new, more reliable diagnostic method. This research is relevant because an
understanding of the metabolic progression of prostate cancer could potentially aid in the
development of a more accurate diagnostic method in the future.

II.

PREVIOUS RESEARCH & STUDY AT HAND

In this topic area, research has been conducted to investigate the reliability of PSA as a
biomarker and to identify other possible biomarkers for prostate cancer. 4-8 Although there is a
solid body of research and review on the identification of alternative reliable biomarkers for
prostate cancer, there has not been a significant amount of research on the metabolic effects of
prostate cancer and how they influence the serum protein composition of these biomarkers,
which is the focus of the study at hand.
Previous research has been done by other researchers in the Landry laboratory to
characterize the proteomic profile of prostate cancer, allowing identification of 51 potential
protein biomarkers for prostate cancer and the development of a protein fingerprint. 9 The protein

7

composition of the human serum of prostate cancer patients was determined by exposing human
blood serum to mesoporous silica nanoparticles (MSNs), resulting in the adsorption of a specific
subset of the proteins present in the serum onto the MSNs. Important to note are the effects of
different nanoparticle properties on the types of proteins that adsorb, thus affecting the protein
fingerprint.10 Thiol-functionalized MSNs were chosen specifically for their ability to capture the
greatest amount of protein relative to other types of nanoparticles, and the porosity of these
particles allowed the capture a greater fraction of low-molecular weight proteins prevalent in
serum that are relevant in disease states.10 Following isolation of the MSNs and extraction and
digestion of the adsorbed proteins, thermogravimetric analysis (TGA) was used to determine the
total mass of protein present in a sample and LC-MS/MS was used to determine the identities of
the proteins present.9 The normalized spectral counts from mass spectrometry were multiplied by
the total mass of protein from TGA to determine the individual protein masses. These data were
then analyzed using the Elastic Net penalized multinomial regression model 9 and compared to
controls (the serum protein composition of cancer-free patients), to identify statistically
significant up- and down-regulated proteins. Z-scores, which represent the number of standard
deviations from the mean, were calculated for each protein where the mean value for a given
protein was taken across all patients in the study, including controls. 9 A characteristic protein
fingerprint for the disease was developed based on the collective Z-scores for each represented
protein (Figure 1).
This research identified 51 proteins that were found to be significantly up or down
regulated in a particular patient group relative to the others, and it was also found that the types
of proteins present strongly related to disease development. 9 Different proteins were seen to
have distinctly different levels of significance in the plasma of patients at different stages of
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prostate cancer. The statistical significance of these 51 proteins, which were identified as either
significantly up- or down-regulated, was determined using the Elastic Net penalized multinomial
regression model. Some proteins in individual patients demonstrated Z-scores of over 4
(meaning 4 standard deviations from the mean), indicating significant dysregulation of that
protein with respect to other patients in the study, as 99.9% of a population is captured within 4
standard deviations from the mean (Figure 1).9 The astounding standard deviations seen in some
of these markers indicate a high level of significance, making them worthwhile candidates for
the investigation of the metabolic consequences of the disease that could produce such
significant levels of these protein products.
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Figure 1a. Heat map representing Z-score values obtained by elastic net penalized multinomial regression model of
51 proteins identified in the serum of prostate cancer patients.9 Proteins and their corresponding molecular weights
(kDa) are listed on the right-hand side of the figure. Patient number is along the x-axis. Significance of each protein
at different disease stages (metastasis, positive biopsy, and negative biopsy) as well is in a control patient is
indicated through color coding of the Z-score, with green indicating up-regulated proteins (Z-score >1) and red
indicating down-regulated proteins (Z-score < -1). Black indicates no statistically significant dysregulation. b. 3D
representation of the heat map illustrating groups of dysregulated proteins based on Z-score. Figures used with
permission.9
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The study at hand aims to elaborate on this past research done by the Landry Group that
identified a baseline protein fingerprint for prostate cancer and will investigate (1) how the
protein fingerprint changes in composition throughout the progression of prostate cancer through
analysis of the proteomic composition of human serum of prostate cancer patients and why such
changes occur from a metabolic perspective and (2) if these protein fingerprints can be used to
distinguish between cancerous disease states. In cancer, the levels of metabolic products (such as
various proteins) of malignant cells can become abnormal, and much of this thesis will comprise
of thorough review of the current scientific literature to determine the significance of proteins
present at abnormal levels and why these proteins might be dysregulated with respect to the
metabolic activity of the malignant cells, providing a better understanding of the metabolic
progression and consequences of the disease which can potentially be used to develop a more
accurate diagnostic method in the future.
In the study at hand, the dysregulated proteins were screened for relevance according to
several different factors, including cancer specificity (relevance to prostate cancer vs. other
cancers), prostate cancer disease stage (metastasis, positive biopsy, negative biopsy, and control),
cellular location, serum concentration by mass, and Z-score. One of the most significant issues in
identifying relevant biomarkers for specific cancers is that there are many peptides and peptide
fragments that are commonly dysregulated in various cancers due to the general health of cancer
patients. An investigation of the specific metabolic mechanism causing a given protein to
become dysregulated can provide insight into which potential biomarkers are worth pursuing as
characteristic of prostate cancer vs other cancers (and could serve as potential novel therapeutic
targets for prostate cancer).
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First, Z-score was considered as proteins that are more significantly dysregulated are
likely to serve as more reliable biomarkers and indicators of disease pathophysiology than
proteins that are only slightly dysregulated with respect to non-disease state concentrations. The
51 proteins were sorted to identify the top and bottom 10% in the positive biopsy and metastasis
groups. The most significantly dysregulated proteins, either upregulated or downregulated, were
determined by identifying the top and bottom 10% in each group.
Cellular location is important, because to develop a proteomic profile for prostate cancer
based on the plasma serum of prostate cancer patients, the relevant biomarkers must be present in
the extracellular fluid as intracellular proteins would not show up in proteomic analysis of
plasma serum. Therefore, in an investigation of these 51 dysregulated proteins, identification of
any intracellular proteins that became detectable in extracellular fluid was significant as it might
relate to the pathophysiology of prostate cancer.
Serum concentration for each protein was calculated using the product of the average
values of the normalized spectral counts (NSpC) and thermogravimetric analysis (TGA) for all
proteins found in protein corona analysis of prostate cancer patient serum samples. This factor is
important to consider because it relates to the sensitivity of detecting biomarkers; dysregulated
proteins present at low concentrations are harder to detect and therefore less reliable than
proteins present at higher concentrations in plasma serum.
Currently, there is only one widely used biomarker to screen for prostate cancer (PSA),
which has been shown to be unreliable as it may be dysregulated in other non-cancerous health
conditions and result in inaccurate diagnoses, negative outcomes for patients, and unnecessary
clinical expenses. Clearly there is a need to identify novel, more accurate biomarkers for prostate
cancer. Other researchers have investigated families of biomarkers for evidence of disease,
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mainly focusing on the presence or absence of prostate cancer in relation to these new
biomarkers and not the stage of disease present (such as metastasis versus positive biopsy, for
example). Evidence shows that families of bloodborne biomarkers change based on disease state.
Therefore, it is expected that each disease state in prostate cancer patients will display a
characteristic set of proteins that are unique from those in other disease states. This analysis
investigates the question, can the disease state of prostate cancer be diagnosed based on families
of biomarkers, i.e., a protein fingerprint? If that is indeed the case, what are the physiological
functions of these biomarkers, and how do these biological mechanisms at work differ between
the cancerous states of metastasis and positive biopsy?

III.

LITERATURE REVIEW & RESULTS

In this study, the proteins that were significantly dysregulated specifically in the two
cancerous disease states for prostate cancer (metastasis and (+) biopsy) were examined in detail
to identify the biological mechanisms altering the proteomic composition in these patients and
how they differ between these two cancerous states, providing a new way of understanding the
metabolic state of prostate cancer patients and the how the disease progresses. Clinically, it is
important to distinguish between disease states as it is relevant to determining the course of
patient treatment, prognosis, and outcome. The top and bottom 10% of dysregulated proteins in
four patient groups (metastasis, (+) biopsy, (-) biopsy, and healthy controls) were identified
(Table 1), compared for similarity, and investigated for the role of the dysregulated proteins in
mechanisms contributing to disease states. For additional data of all of the average Z-scores for
each of the 51 proteins found in each of the four patient groups, see Appendix A.
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Table 1. Top and bottom 10% of dysregulated proteins in metastasis, positive biopsy patient, negative biopsy, and
control groups identified using elastic net penalized multinomial regression statistical model. The Z-scores listed
represent average the Z-score for that protein across all patients in the indicated group.
Metastasis
Top 10%
Gelsolin
Apolipoprotein A-IV
Inter-alpha-trypsin inhibitor heavy chain H1**
Histidine-rich glycoprotein**
Coagulation factor XII

Z-score
2.04550
1.95302
1.95216
1.88158
1.79890

(+) Biopsy
Top 10%
Coagulation factor XI
Plasma serine protease inhibitor**
Filamin-A
Protein HEG homolog 1
Stromal cell-derived factor 1

Z-score
0.93114
0.89584
0.86908
0.84111
0.83894

Bottom 10%
Prothrombin**
Neutrophil defensin 1**
Fibulin-1
Platelet basic protein
Protein AMBP

Z-score
-1.60584
-1.50962
-1.33129
-1.32997
-1.32051

Bottom 10%
Hepcidin
Cystatin-C
Complement component C7
Plasminogen
Apolipoprotein A-IV

Z-score
-0.55623
-0.51891
-0.46808
-0.46232
-0.42674

(-) Biopsy
Top 10%
Hepcidin
Fibulin-1
Ig lambda-3 chain C regions
Complement component C7
Apolipoprotein C-1

Z-score
1.10146
0.957852
0.940796
0.856696
0.850408

Control
Top 10%
Selenoprotein P
Protein AMBP
Haptoglobin-related protein
Ig lambda-1 chain C regions
Immunoglobulin lambda-like
polypeptide 5

Bottom 10%
Gelsolin
Apolipoprotein A-IV
Haptoglobin-related protein
Inter-alpha-trypsin inhibitor heavy chain H1
Histidine-rich glycoprotein

Z-score
-0.487595
-0.458882
-0.431284
-0.403415
-0.401478

Bottom 10%
Proteoglycan 4
Complement C3
Cystatin-C
Beta-2-glycoprotein 1
Ig heavy chain V-I region EU

Z-score
1.09008
1.06105
1.03336
0.935346
0.916202
Z-score
-0.892322
-0.790098
-0.770817
-0.768302
-0.735661

IVa. Metastasis – Top 10% (upregulated proteins)

Gelsolin: Gelsolin was the most significantly upregulated protein in the metastasis patient
group, with an average Z-score of 2.05. Gelsolin exists in two forms, a cytosolic and secreted
form, that are transcribed from the same gene 11. Secreted gelsolin has not been extensively
studied in the prostate cancer disease state, but researchers found that in disease states, gelsolin, a
14

normally harmless protein, can inhibit immunosurveillance and promote cancer progression. 12
This study found that gelsolin was highly expressed in prostate cancer cells and contributed to
cancer progression through several different mechanisms. Researchers found that in vitro,
secreted gelsolin inactivated CD4+ T cells by binding to the surface glycoprotein CD37, induced
apoptosis of activated CD8+ T lymphocytes by binding to Fas ligand, and bound to sortilin (a
membrane glycoprotein) to form a complex with another protein that enhanced endocytosis and
intracellular transport of essential lipids needed to facilitate tumor growth. 12 These researchers
also found that gelsolin is overexpressed in patients with prostate cancer and not in benign
hypertrophic prostate epithelia (PSA is commonly elevated in both cases) and was negatively
correlated with survival. Additionally, pathology studies demonstrated that overexpression of
gelsolin in prostate cancer patients was correlated with significantly higher occurrence of
metastasis.
Apolipoprotein A-IV and inter-alpha-trypsin inhibitor heavy chain H1: Apolipoprotein
A-IV (APOA4) and inter-alpha-trypsin inhibitor heavy chain H1 both had average Z-scores of
1.95 in the metastasis group. These proteins have not been studied for their specific mechanism
in the prostate cancer disease state. One study investigating potential biomarkers for different
cancers found that both proteins may belong to a larger group of proteins that are characteristic
of the cancer state in general. A serum degradome analysis of cancer patients and healthy
controls identified 1373 unique peptides, 40% of the identified peptides originated from five of
the most prominently degraded proteins; fibrinogen alpha chain (FGA), APOA4, complement C3
(C3), apolipoprotein A-I (APOA1) and alpha-1-antitrypsin (SERPINA1). 13 The results on
colorectal cancer (CRC) and prostate cancer peptidome presented by these researchers suggest
that the vast majority of discriminating peptides are not specific to a particular cancer type, rather
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their abundance results from general state of health of cancer patients. Interestingly, the
researchers did suggest one protein fragments out of the hundreds of investigated proteins that
could both differentiate cancer patients from healthy controls as well as colorectal cancer from
prostate cancer; this was peptide ENADSLQASLRPHADEL derived from APOA4, which was
significantly upregulated in prostate cancer patients, and only slightly upregulated in CRC
patients and not at all in controls, and therefore could potentially be regarded as marker specific
to prostate cancer.13
Histidine-rich glycoprotein (HRG): Histidine-rich glycoprotein was upregulated in
metastasis with an average Z-score of 1.88. HRG is an abundant plasma protein with a variety of
functions. Of relevance are its roles in immunity, angiogenesis, and thrombosis, in which HRG
has been found to have both pro- and anti-angiogenic effects, interactions with platelets and
other coagulation factors, and modulation of antitumor immune responses, all processes relevant
to tumor progression in the development of cancer. HRG localizes in the stroma of some tumors
upon release from platelets and may block interaction of anti-angiogenic proteins such as
thrombospondins.14 HRG is thought to interact with thrombospondin and promote angiogenesis
by blocking binding of thrombospondin-1 to the thrombospondin receptor CD36, which is
expressed on a variety of cell types and upon binding of the thrombospondin-1 ligand
counteracts angiogenic signals mediated through growth factor receptors. 15 In the setting of
breast cancer, HRG was found to mask the anti-angiogenic epitope of and co-localize with
thrombsopondin-1 in the tumor matrix.14 By contrast, HRG has also been found to have some
anti-angiogenic activity. Hrg-/- mice with fibrosarcoma had tumor vessels with increased size,
increased production of vascular endothelia growth factor (VEGF) and placental growth factor
(PlGF).16 HRG inhibited both VEGF and PlGF-mediated angiogenesis in-vitro, as well as
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inhibiting endothelial cell chemotaxis, through a mechanism involving the minimal active
domain of the histidine/proline rich region of HRG.17 Angiogenesis is essential for tumor growth
and metastasis, and an “angiogenic-switch” is proposed to occur when pro-angiogenic factors
out-weigh anti-angiogenic factors and promotes tumor progression, and whether or not HRG is
pro- or anti-angiogenic may be highly contextual depending on the tumor environment. 18 In
addition, HRG has been demonstrated to be a potent tumor suppressor by regulating platelet
signaling activity.19 In the absence of HRG, platelet activation becomes enhanced, promoting
tumor metastasis as platelet activation and coagulation play an important role by a proposed
mechanism of shielding circulating tumor cells from detection by the immune system. 20
Interestingly, a study measuring the levels of plasma HRG in ovarian cancer patients found the
same trend as in the study with the prostate cancer patients examined here; HRG was initially
downregulated in earlier disease states, but upregulated in advanced disease states. In the study
presented here, HRG was downregulated in the (-) biopsy, (+) biopsy groups, and then
upregulated in metastasis, and in the ovarian cancer study HRG was downregulated in stage I/II
of ovarian cancer relative to healthy controls and upregulated in stage III ovarian cancer. 21
Altogether, these results make HRG an interesting and seemingly worthwhile biomarker to
continue to research in the context of prostate cancer.
Coagulation factor XII: Coagulation factor XII was upregulated in the metastasis group
with an average Z-score of 1.80, which is not surprising given the role of thrombosis in cancers.
Increased risk of thrombosis is common among cancers, especially once the cancer has
progressed to metastasis. As cells proliferate and tumors grow in size, pieces are prone to break
off and enter the systemic circulation as emboli. As such, it is likely for peptides involved in
thrombosis to be dysregulated in many cancers. However, one study has identified a mechanism
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specifically in prostate cancer cells contributing to the upregulation of FXII. The researchers
identify a novel and unexpected role of the polyP/FXII-driven intrinsic pathway of coagulation
in prostate cancer-associated thrombosis. Coagulation analyses of patient plasma models in
genetically altered mice show that prostate cancer cells and prostasomes expose long-chain
polyP on their surface22. The polymer activates FXII, triggers clotting in prostate cancer patient
plasma, and causes thrombosis in mice 22. These data identify a new coagulation mechanism that
contributes to prostate cancer-driven thrombosis, and the mechanism causing upregulation of this
protein in metastatic disease.

IVb. Metastasis – Bottom 10% (downregulated proteins)

Prothrombin: Prothrombin was the most significantly downregulated protein in the
metastasis group, with an average Z-score of -1.61. This is interesting because it has been found
that thrombin generation is increased in men with advanced prostate cancer. 23 A study
investigating the role of prothrombin in prostate cancer found that thrombin induced the
expression and secretion of interleukin 8 (IL-8) and vascular endothelial growth factor (VEGF),
two cytokines which promote prostate cancer growth and angiogenesis, suggesting a mechanism
by which thrombin may contribute to the progression of prostate cancer. 24 These data seem to
suggest that prothrombin should be upregulated in prostate cancer disease states, and
prothrombin is in fact slightly upregulated in the (+) biopsy group, prompting further
investigation of why prothrombin is downregulated in the metastasis group.
Neutrophil defensin 1: In the study of prostate cancer patients presented here, neutrophil
defensin 1 was downregulated in the metastasis group with an average Z-score of -1.51.
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However, it has been proposed that human neutrophil proteins 1, 2, and 3 are expressed in
several tumor types, and human neutrophil peptides (α-defensin-1, -2, and -3) were found to be
present in significantly elevated concentrations in the plasma from colorectal cancer patients 25
and in patients with metastatic bladder cancer26. More research is needed to investigate the
mechanism resulting in the downregulation of neutrophil defensin 1 specifically in the context of
metastatic prostate cancer.
Fibulin-1: Fibulin was downregulated in the metastasis group with an average Z-score of
-1.33. Fibulin is downregulated by the inflammatory cytokines CXCL1/GROα through
epigenetic regulation. CXCL1/GROα is associated with increased AKT activation and IkB
kinase α phosphorylation, resulting in activation of nuclear factor-kappa B (NF-kB), which
interacts with histone deacetylase 1 (HDAC1) to form a gene-silencing complex that decreases
acetylation of histone H3 and H4 on the NF-kB-binding site on the fibulin-1 promotor, 27 thus
repressing the expression of fibulin-1. Kuo et al. provide the first evidence that CXCL1/GROα
specifically decreases fibulin-1 expression in prostate cancer cells and suggest that inhibition of
the CXCL1/GROα-mediated AKT/NF-kB signaling pathway may be a potential therapeutic
target for prostate cancer. 27 Another study identified fibulin-1 as a human bone marrow stromal
cell-derived factor that induces apoptosis of prostate cancer cells. 28 Fibulin-1 is a clear example
of how the downregulation of a peptide can permit the continued survival and proliferation of
malignant cancer cells.
Platelet basic protein and protein AMBP: Platelet basic protein and protein AMBP were
found to be downregulated in the metastasis patient group, with average Z-score of -1.33 and 1.32, respectively. A clear role these proteins in the progression of prostate cancer, or indeed in
any type of cancer, has not yet been identified, and further research is needed. At this time, these
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biomarkers may primarily fulfill a diagnostic role in the protein fingerprint for metastatic
prostate cancer as statistically significant biomarkers.

IVc. (+) Biopsy – Top 10% (upregulated proteins)

Coagulation factor XI: Coagulation factor XI (FXI) was the most upregulated protein in
the (+) biopsy group, with an average Z-score of 0.93, which is logical given the previously
discussed role of thrombosis in cancers. FXI is the substrate of FXII leading to fibrin formation.
As seen previously, FXII was significantly upregulated in metastasis as a result of the exposure
of the activator polymer long-chain polyP on the surface of the plasma membrane of prostate
cancer cells. In addition, polyP accelerates other downstream mechanisms for pro coagulation
including FXI feedback activation, leading to upregulation of FXI protein. 22 Interestingly, FXII
was upregulated in metastasis but slightly downregulated in (+) biopsy, and FXI was essentially
not dysregulated at all in metastasis but was significantly upregulated in (+) biopsy. This could
possibly be the result of greater consumption of FXI substrate by FXII in metastasis, but further
research is needed to investigate the relationship between these two coagulation factors in the
context of prostate cancer.
Plasma serine protease inhibitor: Plasma serine protease inhibitor was found to be
significantly upregulated in (+) biopsy with an average Z-score of 0.90, and the current literature
shows unclear data about the role of this type of peptide in prostate cancer. These peptides are
expressed by most epithelial cells. Hepatocyte growth factor activator inhibitor type 1 (HAI-1) is
a type I transmembrane serine protease inhibitor that is the cognate inhibitor of the serine
protease matriptase and was first identified in a human gastric cancer cell line. 29 Recent studies
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have suggested the importance of the matriptase/HAI-1 balance in the progression of various
cancers.30 In one study examining this relationship, it was found that HAI-1 expression levels
were significantly higher in all proliferative prostate diseases (including benign prostate
hyperplasia as well as localized and metastasized cancers). 31 Additionally, studies investigating
the suppression of HAI-1 using HAI-1 deficient prostate cancer cell lines found that these cancer
cells displayed decreased invasiveness and slower growth compared to controls, suggesting that
loss of HAI-1 can lead to more aggressive phenotypes. 32 Yet, other studies have found that in
prostate cancer tissues and cell lines, expression of the serine protease matriptase is significantly
increased and correlates with a corresponding decrease in the expression of the serine protease
inhibitor HAI-1.33 Suggested explanations for these inconsistencies between studies are small
patient numbers, different patient populations and different assays used in the detection of the
peptides. It is also possible that dysregulation of HAI-1 is a marker of abnormal prostate
epithelial cell proliferation independent of cancer phenotype.
Filamin-A: Filamin A (FLNA) was found to be upregulated in the (+) biopsy group with
an average Z-score of 0.87. FLNA is a well-characterized actin protein involved in cross-linking
and cell scaffolding and has functions in cell motility and adhesion. Multiple studies have found
FLNA to be overexpressed in prostate cancer,34, 35 as is seen here. An investigation of the clinical
significance of filamin A (FLNA) in prostate cancer found that FLNA may have a dual role in
cancer progression by either promoting or suppressing tumor progression depending on the
localization of the protein (either to the cytoplasm or within the nucleus) and its regulation of the
human androgen receptor (hAR).36 The majority of FLNA is localized to the cytoplasm as a fulllength peptide, where it interacts with the hAR36 and influences the hepatocyte growth factor
(HG)/c-MET axis,35 ultimately resulting in the promotion of tumor growth by inducing cell
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invasion and migration. On the other hand, FLNA is highly susceptible to proteolysis, and the
cleavage product is localized to the nucleus rather than the cytoplasm where it may act to
suppress tumor growth and metastasis by interactions with transcription factors resulting in
apoptosis and cell death.34 In metastatic tissue, FLNA is primarily localized to the cytoplasm,
while in localized prostate cancers, neoplasia, and normal tissues, FLNA is mostly nuclear.
FLNA expression was found to be significantly decreased in prostate cancer tissues relative to
normal tissues and that overexpression of FLNA in prostate cancer cell lines resulted in lower
cell survival fraction, decreased migration and invasion, and lower expression of the matrix
metallopeptidase 9 (MMP-9),37 a peptide belonging to a class of enzymes involved in
degradation of the cellular matrix in physiological processes such as cell migration (relevant to
metastasis) and remodeling during angiogenesis (relevant to tumor progression). Further research
is needed to determine how serum concentrations of FLNA correlate to the intracellular
concentrations described here. Overall, these results suggest that FLNA correlates with prostate
cancer disease stage and serves as a negative regulator of prostate cancer, making it a useful
biomarker in the context of a protein fingerprint that could be indicative of disease state.
Protein HEG homolog 1 (HEG1): HEG1 1 was seen to upregulated in the (+) biopsy
group with an average Z-score of 0.84. This peptide has not been studied for its role in the
context of prostate cancer, but studies of malignant mesothelioma found that HEG1 is involved
in cell proliferation of malignant cells through a mechanism involving microRNA-23b. 38 In the
study of malignant mesothelioma cells, Fujii et. al. demonstrated that HEG1 contains epidermal
growth factor-like domains that influence cancers through aberrant signaling during cell
adhesion and protection from invasion of tumor cells, thus supporting the survival and
proliferation of malignant cells. This study found that cell proliferation significantly decreased
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following transfection with microRNA-23b inhibitor and/or HEG1 siRNA, and that suppression
of microRNA-23b and/or HEG1 resulted in apoptosis through the induction of LC3-II, a protein
involved in autophagy.38 Together these results demonstrate that HEG1 and HEG1 mediated
microRNA-23b signaling contribute to cell proliferation via evasion of apoptosis and autophagy
in malignant cells. Further research is needed to identify if this is the same mechanism in
prostate cancer cells.
Stromal cell-derived factor 1 (SDF1): SDF1 was found to be upregulated in the (+)
biopsy group, with an average Z-score of 0.84. There is evidence that overexpression of the
SDF1/CXCR4 (chemokine receptor type 4) axis is involved in the promotion of prostate tumor
growth, localization of prostate cancer cells to bone, and facilitation of interactions between
malignant cells and the bone environment, possibly helping to facilitate the transition from (+)
biopsy to metastasis. This is especially significant given that in prostate cancer, metastatic
disease is one of the leading causes of cancer-related death, and the primary location of
metastasis in prostate cancer is bone.39 Studies have demonstrated that SDF1 signaling can be
activated by chemokine receptor type 4 (CXCR4) in prostate cancer cells via the loss of the
tumor suppressor phosphatase and tensin homolog (PTEN) and resultant activation of the
PI3K/Akt pathway which regulates SDF1/CXCR4 signaling.40 SDF1 is produced by vascular
endothelial cells and increases expression of the β 3 subunit of αv β3 receptors in prostate cancer
cells, increasing the adhesiveness and invasiveness of these cells, and simultaneously induces
expression and blockade of the cell adhesion molecule CD164 in prostate cancer cells, 39
decreasing their ability to adhere to endothelial cells in bone marrow and enhancing metastatic
behavior. Additionally, silencing of CXCR4 was found to lead to a significant decrease in VEGF
secretion and MMP-9 (which was previously seen to be downregulated by FLNA in the
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suppression of tumor progression), resulting in delay of tumor growth, while higher levels of
CXCR4 activity were associated with mitotic dormancy that facilitated colonization of the bone
marrow by tumor cells in prostate cancer.39 These data suggest that SDF1 is an important protein
contributing to tumor progression in the development of prostate cancer.

IVd. (+) Biopsy – Bottom 10% (downregulated proteins)

Hepcidin: Hepcidin was the most significantly downregulated protein in the (+) biopsy
patient group, with an average Z-score of -0.56. This is interesting because multiple studies have
demonstrated the opposite, the overexpression of hepcidin in both malignant and metastatic
prostate cancer.41-43 One study found that hepcidin-silenced prostate cancer cells had
significantly lower iron levels and reduced expression of ferroportin (an iron transporter), and
that hepcidin-silenced cells treated with exogenous iron had significantly greater proliferative
capacity and a higher migration rate.41 The researchers proposed that hepcidin is involved in the
onset of prostate cancer through a mechanism involving downregulation of ferroportin
expression and increased intracellular iron levels to enhance cell proliferation, migration, and
evasion of apoptosis by cancer cells. Another study found that prostate epithelial cells synthesize
their own hepcidin (through a unique intersection of pathways involving BMP4/7, IL6, Wnt, and
the agonist of both BMP and Wnt, SOSTDC1), and that hepcidin synthesis and secretion are
significantly increased in prostate cancer cells and tissues and promote prostate cancer growth
and progression by the same mechanism described above, by decreasing cell surface ferroportin
and increasing intracellular iron retention.43 It is unclear why in the protein fingerprint generated
here hepcidin was found to be downregulated in every patient in both the (+) biopsy and
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metastasis groups. Further analysis with a greater number of patients is needed to confirm these
findings.
Cystatin C: Cystatin C was downregulated in the (+) biopsy patient group, with an
average Z-score of -0.52. Cystatin C is a secreted cysteine protease inhibitor and that processes
including neutrophil chemotaxis, tissue inflammation, resistance to infections, and bone
resorption (as such, this protein has been proposed as a biomarker for increased osteoblastic
activity in prostate cancer patients who have progressed to the metastasis disease state). Cystatin
C has previously been found to be downregulated in prostate cancer, and one group of
researchers proposed that cystatin C prevents tumor progression by exerting influence on the
MAPK/Erk (specifically by inducing Erk2 inhibitor, thus inhibiting MAPK/Erk2 activity) and
androgen receptor pathways in the invasion of prostate cancer cells. 44 Researchers found that
cystatin C expression was inversely correlated with matrix metalloproteinase 2 (MMP-22),
which along with MMP-9 discussed above in the context of upregulation of filamin A in (+)
biopsy, is a protein that contributes to tumor progression and metastasis. In vitro experiments
showed that silencing of cystatin C using siRNA resulted in increased invasiveness of prostate
cancer cells, while overexpression of cystatin C significantly reduced the invasiveness of
malignant cells.44 Researchers also found that tissue expression of androgen receptor (AR) is
inversely correlated with cystatin C expression, and that overexpression of AR is a mechanism
that further enhances tumor progression by overcoming the inhibiting effects of transforming
growth factor beta 1 (TGFbeta1), which induces growth inhibition and apoptosis. 45 Cystatin C
expression was significantly lower in malignant than benign tissues, and decreased cystatin C
levels correlated with lower patient survival, suggesting the relevance of using cystatin C as a
biomarker to discriminate between cancerous and non-cancerous prostate disease states.
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Plasminogen: Plasminogen was found to be downregulated in the (+) biopsy group, with
an average Z-score of -0.46. One study measuring the expression of urokinase-type plasminogen
activator system members (including urokinase-type plasminogen activator (uPA), uPA-receptor
(uPAR), and plasminogen activator inhibitor-1 (PAI-1)) in prostate cancer patients demonstrated
that these proteins have important roles in prostate cancer tumor progression through regulation
of a uPA/uPAR/PAI-1 axis via both autocrine and paracrine mechanisms. 46 Urokinase-type
activator (uPA) is a serine protease that activates plasminogen by catalyzing the conversion of
plasminogen to plasmin, which degrades various matrix proteins. The binding of uPA to the
uPAR also results in signaling cascades leading to angiogenesis, 47 chemotaxis,48 cell adhesion,49
and cell proliferation.50 Researchers found that uPA was overexpressed in prostate cancer cells,
both in primary prostate cancer and metastasis, and silencing of uPA in prostate cancer cells in
vivo using siRNA resulted in decreased uPA, suppressed uPAR, and resulted in significant
reduction of prostate tumor growth.46 Given that plasminogen is the substrate of uPA, it is logical
that overexpression of uPA resulted in the downregulation of plasminogen seen in the (+) biopsy
group examined here. Interestingly, the researchers found that PAI-1 was also overexpressed in
prostate cancer cells, which they found was due to soluble factors that stimulated PAI-1 gene
transcription in bone cells (subsequently, uPA silencing by PAI-1 then led to reduction of PAI-1
expression).46 This suggests that plasminogen could briefly become less significantly
downregulated, depending on the amount of circulating PAI-1. Altogether, these data suggest
that prostate cancer-cell mediated dysregulation of proteins in the enzymatic cascade in which
plasminogen is a component are the source of dysregulation of plasminogen.
Complement component C7: Complement component C7 was found to be downregulated
in the (+) biopsy group, with an average Z-score of -0.46. Complement C7 has been identified by
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multiple studies as a potential tumor suppressor.51, 52 Researchers found that C7 expression was
significantly lower in prostate cancer cells than in normal tissues, that lower expression was
correlated with higher clinical T stage (referring to the size and extent of the main tumor), and
that C7 was significantly correlated to nine cell signaling pathways (including cytokine/cytokine
receptor interaction, focal adhesion, chemokine signaling, calcium signaling, JAK stat signaling,
cell adhesion, axon guidance, leukocyte transendothelial migration, and vascular smooth muscle
contraction pathways).51 The researchers did not identify the mechanism causing downregulation
of C7, but did point out genetic alteration was found in 26 of 136 (19%) prostate cancer patients,
with the most common mutation being a missense mutation. 51 Further research is needed to
identify the mechanism resulting in the downregulation of complement C7 in prostate cancer.
Apolipoprotein A-IV (APOA4): APOA4 was found to be downregulated in the (+) biopsy
group, with an average Z-score of -0.43. Important to note, this was the only biomarker in
common between the metastasis and (+) biopsy groups top/bottom 10% and was oppositely
dysregulated between these two groups (average Z-score for APOA4 in metastasis was 1.95).
APOA4 is a lipid-binding protein synthesized in the small intestine which is packaged into
chylomicrons and is present on chylomicron remnants and high-density lipoproteins as well as in
lipid-free form in systemic circulation.53 APOA4 has many identified physiological roles; one
that could potentially be relevant to prostate cancer is its role in platelet aggregation and
thrombosis. ApoA-IV negatively regulates αIIbβ3-mediated platelet aggregation and
thrombosis.54 However, study of this pathway specifically in prostate cancer patients is needed to
identify if APOA4 has any sort of relevance in this context. Given the diverse functions and
locations of APOA4, it could simply be dysregulated in prostate cancer due to the dysregulation
of various other biological pathways that interact with or influence this peptide.
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IV.

DISCUSSION

The questions central to this study were can different families of protein biomarkers be
used to diagnose specific disease states, specifically metastatic versus malignant prostate cancer,
and why are various proteins found to be dysregulated in these disease states?
The answers are complex; immediately of interest is that there are no proteins in common
between the (+) biopsy and metastasis groups top and bottom 10% except apolipoprotein A-IV,
which is upregulated in metastasis and downregulated in (+) biopsy. This suggests significant
changes or differences in the metabolic processes occurring in the body during different disease
states as the prostate cancer progresses and supports the development of unique protein
fingerprints to accurately predict disease state and discriminate between metastasis and (+)
biopsy. On the other hand, several biomarkers were commonly downregulated across the (+)
biopsy, (-) biopsy, and control groups. Cystatin C was downregulated in both the (+) biopsy and
control groups, and plasminogen and apolipoprotein A-IV were both downregulated in (+)
biopsy and (-) biopsy groups. While this isn’t relevant to the conversation about discriminating
between metastatic and (+) biopsy disease states, this predicts potential difficulty in using these
specific biomarkers to discriminate between the disease and non-disease states of (+) and (-)
biopsy, such as is commonly needed to distinguish a malignant tumor from benign prostatic
hyperplasia and suggests the need for further analysis to determine if there is a significant
threshold level to identify disease state despite these being similarly dysregulated between
disease and non-disease state groups.
Which of the investigated proteins would make good biomarkers for prostate cancer?
Primarily, proteins that are statistically significantly dysregulated, proteins that have a role in a
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mechanism relevant to prostate cancer (specificity), and that are present at a detectable level in
plasma are great candidates. One thing to consider about the protein biomarkers investigated here
is that these peptides specifically resulted from the unique method used to extract them (thiolfunctionalized MSNs were used for their demonstrated ability to capture low-molecular weight
proteins). Other methods investigating serum protein composition in prostate cancer patients
might yield slightly different results, depending on the methods used to identify the proteins
present. This leads us to the question, should we rely only on proteins that have a clearly defined
role in prostate cancer, or can simply diagnostic markers (i.e. markers that do not have a clearly
defined role in prostate cancer or are common to other cancers as well) be just as accurate?
Further studies repeating the methods used here are needed to further validate the data by
increasing the number of patients, and thus serum samples, and increasing the confidence in the
results obtained in this analysis. Additionally, investigation of the serum levels of the 51 peptide
biomarkers identified in the heat map for prostate cancer in patient groups with other cancer
types would help to identify biomarkers that are potentially specific to prostate cancer.
How many biomarkers are needed to achieve high-accuracy and consistently reliable
diagnosis? Although more data is needed to determine the ideal number of biomarkers to form
the fingerprint that would be used to screen patients, the past unreliability of PSA demonstrates
the need to rely on more than one biomarker to diagnose prostate cancer. A fingerprint relying on
potentially dozens of biomarkers would provide a novel approach that could help to reduce the
prevalence of inaccurate diagnoses (both false positives and incorrect negatives) by allowing
patients to vary in serum levels of one or more biomarkers, a natural phenomenon in humans that
all differ with respect to metabolism and possible comorbidities, while overall still demonstrating
good correlation to the determined fingerprints. In the study analyzed here, over 400 proteins
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were initially screened, of those 51 were determined to be significantly dysregulated, 9 and
approximately 20 were analyzed here, suggesting that a relatively small subset might be
indicative of disease and sufficient to create an accurate fingerprint.
Also,worth noting is that the Z-score values, while fairly significant for the most
dysregulated proteins in the metastasis group (ranging from around 1.5 to 2 standard deviations
away from the mean), were less significant for the most dysregulated proteins in the (+) biopsy
group (ranging approximately 0.5 to <1 standard deviation from the mean). These statistics
suggest that the protein fingerprint for metastasis would have more diagnostic power as a test for
the metastatic disease state than the protein fingerprint for (+) biopsy. Yet, given the need to
catch cancer early to improve patient outcomes, the goal would be to diagnose prostate cancer
before it achieves metastasis. Therefore, relying on correlation to a greater number of proteins
seems appropriate, especially in the (+) group where patients are apparently less likely to have
significant dysregulation in the proteomic composition.
The major limitation to this study was the utilization of a small patient group. There was
a total of 22 patients used in this study. While average values were used for Z-score across
patient groups for each disease state, high outliers (Z-scores of >4 or <-4) had the potential to
inflate Z-score values than if a larger patient group was used. The small number of patients
might also be able to explain some of the discrepancies seen where the direction of dysregulation
didn’t correspond with the current scientific literature. In addition, this study compared prostate
cancer patients to healthy controls and did not compare to other cancer patient groups. This
makes it difficult to identify biomarkers unique to prostate cancer based off statistical data alone.
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V.

CONCLUSIONS & FUTURE DIRECTIONS

In conclusion, current literature clearly shows the need for a more reliable diagnostic test
for prostate cancer than the current PSA test to increase diagnosis accuracy and improve
prognosis through earlier identification of and higher specificity for prostate cancer. A protein
"fingerprint" identifies a characteristic set of proteins indicative of disease. In this analysis,
different proteins were seen to have distinctly different levels of significance in the plasma of
patients at different stages of prostate cancer. This is promising evidence for the potential use of
protein fingerprints specific to each disease state and the ability to diagnose a patient’s stage of
cancer (metastasis, positive biopsy) and differentiate from certain non-disease states such as
benign prostatic hyperplasia (negative biopsy). Additionally, peptide biomarkers were
investigated for the specific mechanisms resulting in their dysregulation in the context of
prostate cancer, elucidating some of the physiological processes that are occurring in each
disease state and contributing to a greater understanding of the way in which prostate cancer
progresses.
Future research is needed with a larger patient group to reproduce and expand on the data
presented here. A patient group of 55 participants has been identified at the University of
Vermont Medical Center as highly genetically pre-disposed for developing prostate cancer and
would serve as a good resource for this research. Groups such as this would provide an excellent
opportunity for a longitudinal study, such as an observation cohort study, to identify trending
biomarkers over time and distinguish “delta values,” or how quickly each protein biomarker is
changing in its level of significance of dysregulation over time. For example, repeatedly
analyzing the biomarkers of interest in a group of (+) biopsy patients over a significant period
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would clearly indicate how quickly these proteins are becoming dysregulated. Future analysis
using the same methods as described in this analysis to compare protein fingerprints in noncancerous disease states, such as negative biopsy and benign prostatic hyperplasia, is needed to
help identify the biological mechanisms that differ for non-cancerous disease states as well. The
development and comparing of protein fingerprints of different cancer types would also be useful
to help distinguish biomarkers specific to prostate cancer versus other cancers, and which
biomarkers are common to multiple cancer types. The development of “control fingerprints,” in
which the average Z-score of each protein is set to zero in the control patient group, would
provide a different way to look at the dysregulation of the proteins in the fingerprint (in this
study, the Z-scores were calculated relative to an average taken across all patients in the study.
Therefore, proteins were also necessarily apparently up- and down-regulated in controls as well).
Another interesting angle to investigate would be to include the PSA levels of these patients in
this study and to compare the rate of dysregulation of the protein biomarkers to the amount of
change in PSA levels. Additionally, further studies comparing the power of various families of
biomarkers (such as peptides compared to miRNA) to accurately predict disease are needed to
identify the most worthwhile biomarker candidates to pursue in the context of prostate cancer.
Ultimately, the analysis of the proteomic profile and composition in prostate cancer
patients presented here demonstrates the relevance of certain proposed biomarkers to the
physiological mechanisms in the cancerous disease states, demonstrates the specificity of protein
fingerprints for different disease state (metastasis, (+) biopsy, and (-) biopsy), and reinforces the
validity of pursuing families of peptide biomarkers found in human serum to generate a protein
fingerprint characteristic of prostate cancer, with the goal of future application as a less-invasive
diagnostic method providing the earlier detection and more accurate diagnosis of prostate cancer
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and thus improving both patient prognosis and psychological well-being. The greater
understanding of the biological mechanisms resulting in the dysregulation of the proteomic
profile presented here also presents potential opportunities for the identification of novel
therapeutic targets in prostate cancer.
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VII.

SUPPLEMENTAL DATA

Appendix A. Average Z-score values for each protein within the specified patient group (metastasis, (+) biopsy, (-)
biopsy, and control). The top and bottom 10% of proteins (i.e., the most statistically significantly up- and downregulated proteins) are highlighted within each patient group. The top 10% are highlighted green while the bottom
10% are highlighted red.
PT GROUP AVG + GROUP SPECIFIC +/-10%
METASTASIS (+) BIOPSY
(-) BIOPSY
CONTROL
0.396982523
0.805209491
1.952159967
1.953023229
2.045496541
1.881577337
1.798898278
1.631240511
-0.993802527
-1.320506835
-0.275101847
-0.474018854
-0.304014084
-0.406654571
-0.667813028
-0.619785052
0.185069859
0.210349176
-0.698657238
-0.379228924
-0.325903472
-0.314602472
-0.315415646
-0.464665391
-0.535207477
-0.084878553
-0.307743559
-0.248416615
-0.73566082
-0.786466044
-1.259394798
-0.79793323
-0.421916409
-1.5096161
-1.605839416
-0.29292294

-0.462319313
-0.215840045
-0.404240234
-0.426738842
-0.389038758
-0.385438293
-0.271553522
-0.518913067
-0.28964158
-0.12143411
-0.275101847
-0.041951864
-0.253045213
0.72500378
0.64416359
0.68558344
0.256863521
-0.05335261
-0.115844262
0.757345068
0.869075924
0.838939925
0.84110839
0.746459088
0.738509972
0.931144651
0.820649491
0.662444308
0.544644784
0.807387435
0.721089013
0.895841793
0.819259856
0.729673406
0.509309657
-0.29292294

-0.340403189
-0.017057411
-0.403414587
-0.45888192
-0.487595384
-0.401478266
-0.344482967
0.063228514
0.037520775
0.1007687
-0.275101847
-0.431284159
-0.263811424
-0.303333877
0.071916017
0.090784187
0.222864509
0.562904418
0.847143297
-0.190143436
-0.325903472
-0.314602472
-0.315415646
-0.002745954
0.055115352
-0.266977476
-0.307743559
-0.248416615
0.479011239
0.138186235
0.164455222
-0.334221677
-0.248534197
0.284302118
0.259982588
0.627692013

0.713761622
-0.361279165
-0.511859271
-0.407897285
-0.486917186
-0.480666346
-0.630978242
-0.770816648
1.090082832
1.061050219
0.935346281
1.033355141
0.916201515
-0.12001345
-0.33942831
-0.453969949
-0.768302425
-0.892322394
-0.488061711
-0.339230133
-0.325903472
-0.314602472
-0.315415646
-0.520174257
-0.535207477
-0.675702272
-0.307743559
-0.248416615
-0.73566082
-0.533152816
-0.088028289
0.031246781
-0.297630824
-0.065938172
0.309524321
-0.29292294
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PROTEINS
Plasminogen
Hepatocyte growth factor activator
Inter-alpha-trypsin inhibitor heavy chain H1
Apolipoprotein A-IV
Gelsolin
Histidine-rich glycoprotein
Coagulation factor XII
Cystatin-C
Selenoprotein P
Protein AMBP
Ig lambda-1 chain C regions
Haptoglobin-related protein
Immunoglobulin lambda-like polypeptide 5
Ig kappa chain V-III region GOL
Cartilage oligomeric matrix protein
Serotransferrin
Beta-2-glycoprotein 1
Proteoglycan 4
Insulin-like growth factor-binding protein 5
Complement C5
Filamin-A
Stromal cell-derived factor 1
Protein HEG homolog 1
Coagulation factor V
Platelet factor 4 variant
Coagulation factor XI
Multimerin-1
Protein Wnt-3a (Fragment)
Ig heavy chain V-I region EU
Complement factor B
Ribonuclease 4
Plasma serine protease inhibitor
Alpha-2-antiplasmin
Neutrophil defensin 1
Prothrombin
Ig lambda chain V-III region LOI

-0.797441669
-1.179275601
-0.721912407
-0.314982789
-0.308596121
-0.25593189
-0.27859434
-0.307944315
-0.316130282
-0.801503239
-0.71125986
-1.27097777
-1.331293523
-0.934966529
-1.329966954

0.042636624
0.510851872
-0.277825075
-0.314982789
-0.286179957
-0.25593189
-0.27859434
-0.307944315
-0.316130282
-0.234678017
-0.307089601
-0.468084189
-0.258530256
-0.556230091
-0.020840033

0.723320292
0.800354232
0.940796233
0.674963119
0.642063546
0.548425478
0.596987872
0.659880674
0.677422032
0.158630107
0.850408431
0.856696359
0.957851926
1.101458398
0.785827599

-0.425859022
-0.79009769
-0.40619471
-0.314982789
-0.308596121
-0.25593189
-0.27859434
-0.307944315
-0.316130282
0.700734061
-0.253056394
0.379108341
0.034278429
-0.126592426
-0.011177036

39

Liver-expressed antimicrobial peptide 2
Complement C3
Ig lambda-3 chain C regions
Ig lambda chain V-I region WAH
Cartilage acidic protein 1
Ig kappa chain V-I region WAT
Serum amyloid P-component
Cathelicidin antimicrobial peptide
Out at first protein homolog
Apolipoprotein C-II
Apolipoprotein C-I
Complement component C7
Fibulin-1
Hepcidin
Platelet basic protein

